Cancer targeted therapeutics: From molecules to drug delivery vehicles
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
The pitfall of all chemotherapeutics lies in drug resistance and the severe side effects experienced by patients. One way to reduce the off-target effects of chemotherapy on healthy tissues is to alter the biodistribution of drug. This can be achieved in two ways: Passive targeting utilizes shape, size, and surface chemistry to increase particle circulation and tumor accumulation. Active targeting employs either chemical moieties (e.g. peptides, sugars, aptamers, antibodies) to selectively bind to cell membranes or responsive elements (e.g. ultrasound, magnetism, light) to deliver its cargo within a local region. This article will focus on the systemic administration of anti-cancer agents and their ability to home to tumors and, if relevant, distant metastatic sites.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712 · cited 2×
“Some other particles in clinical trials such as Merrimack MM-398 (liposome loaded with irinotecan) for pancreatic cancer in Phase III trial [115] and Abraxane with gemcitabine has been approved for treating pancreatic cancer [116].”
BackgroundRecent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Drug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552 · cited 1×
“In tumor pathology, angiogenesis, or new blood vessel formation, results in abnormally constructed vessels with large vascular fenestrae (as large as 600 nm) and impaired lymphatic drainage [68].”
BackgroundRenal clearance of quantum dots
Soo Choi, H., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G., & Frangioni, J. V. (2007) · Nature Biotechnology · doi:10.1038/nbt1340 · Cited by 4,476 · cited 1×
“The liver (~107 nm) [70], kidney (~5 nm) [71, 72], and spleen (~110 nm) also exhibit large fenestrae, which allow chemotherapeutic nanoparticles accumulation and toxicity [73].”
BackgroundEnhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834 · cited 1×
“Trastuzumab-emtansine Trastuzumab for targeting HER2 and mertansine as a cytotoxic agent Treatment of HER2-positive metastatic breast cancer (mBC) [45]”
BackgroundChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · cited 1×
“T cells, that can recognize tumor antigen can be used as a cell therapy and for drug delivery purposes [159-161]”
BackgroundThe effect of particle design on cellular internalization pathways
Gratton, S. E. A., Ropp, P. A., Pohlhaus, P. D., Luft, J. C., Madden, V. J., Napier, M. E., & DeSimone, J. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801763105 · Cited by 2,918 · cited 1×
“Elongated shapes may also provide benefits to internalization, as 150 nm (AR=3) rod-like particles exhibit higher internalization rates of HeLa cells compared to nanospheres [109].”
BackgroundEfficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623 · cited 1×
“cutaneous T-cell lymphoma (CTCL) and T-cell lymphoma [31] (6)34”
BackgroundHe, C., Hu, Y., Yin, L., Tang, C., & Yin, C. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.01.065 · Cited by 2,607 · cited 1×
“either increase, decrease, or have no impact on the blood clearance of nanoparticles, but positive charges generally have a negative effect upon exposure to plasma [99].”
Background
Cited by
Park, J., Choi, Y., Chang, H., Um, W., Ryu, J. H., & Kwon, I. C. (2019) · Theranostics · doi:10.7150/thno.37198 · Cited by 382
Synthesis of chitosan aerogels as promising carriers for drug delivery: A review
Wei, S., Ching, Y. C., & Chuah, C. H. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2019.115744 · Cited by 285
Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery: An update
Castillo, R. R., Lozano, D., González, B., Manzano, M., Izquierdo-Barba, I., & Vallet-Regí, M. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1598375 · Cited by 197
Mosafer, J., Teymouri, M., Abnous, K., Tafaghodi, M., & Ramezani, M. (2017) · Materials Science and Engineering: C · doi:10.1016/j.msec.2016.11.053 · Cited by 60
“Chemotherapy has mainly failed in treating such tumors due to the poor glioma targeting of the chemotherapeutics, limited drug penetration across the BBB(8) and serious side effects [1].”
Background
Metadata
- Authors
- Liu, D., & Auguste, D. T.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2015-12
- Volume
- 219
- Pages
- 632-643
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W1208915593
- Cited by
- 112
- References
- 21
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.